Literature DB >> 19160301

Interventions for treating painful sickle cell crisis during pregnancy.

Arturo J Martí-Carvajal1, Guiomar E Peña-Martí, Gabriella Comunián-Carrasco, Arturo J Martí-Peña.   

Abstract

BACKGROUND: Sickle cell disease is a group of genetic haemoglobin disorders. All over the world, about 300,000 children with these disorders are born each year. Acute sickle cell pain episodes are the most common cause of hospitalisation. Pregnancy in women with sickle cell disease is associated with an increased incidence of maternal and fetal morbidity and mortality. The painful crisis is a severe complication of this illness, and it requires several interventions: packed red cell transfusion, fluid replacement therapy, analgesic drugs, oxygen therapy and steroids; but the approach is not standardised.
OBJECTIVES: To assess the effectiveness and safety of different regimens of packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesic drugs, and steroids for the treatment of painful sickle cell crisis during pregnancy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (December 2007), the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register (October 2007), LILACS database (1982 to December 2007) and the following web sites: ClinicalTrials.gov (http://www.clinicaltrials.gov) (December 5, 2007); Current Controlled Trials (http://controlled-trials.com/) (December 5, 2007), and Sistema de Información Esencial en Terapéutica y Salud (http://www.icf.uab.es/informacion/Papyrus/sietes.asp) (December 1, 2007). We also handsearched the European Haematology Association conference (June 2007), the American Society of Hematology conference (December 2007) and reference lists of all retrieved articles. SELECTION CRITERIA: We intended to include randomised clinical trials. DATA COLLECTION AND ANALYSIS: We intended to summarise data by standard Cochrane Collaboration methodologies. MAIN
RESULTS: We could not find any randomised clinical trials on interventions (packed red cell transfusion, oxygen therapy, fluid replacement therapy, analgesic drugs, and steroids) for the treatment of painful sickle cell crisis during pregnancy. AUTHORS'
CONCLUSIONS: This review found no randomised clinical trials on the safety and efficacy of interventions for treating painful sickle cell crisis during pregnancy. The effects of interventions need to be tested in randomised clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19160301     DOI: 10.1002/14651858.CD006786.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  6 in total

Review 1.  Fluid replacement therapy for acute episodes of pain in people with sickle cell disease.

Authors:  Uduak Okomo; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

2.  Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.

Authors:  Patricia M Fortin; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-08-01

Review 3.  Does TENS Reduce the Intensity of Acute and Chronic Pain? A Comprehensive Appraisal of the Characteristics and Outcomes of 169 Reviews and 49 Meta-Analyses.

Authors:  Carole A Paley; Priscilla G Wittkopf; Gareth Jones; Mark I Johnson
Journal:  Medicina (Kaunas)       Date:  2021-10-04       Impact factor: 2.430

4.  Successful epidural analgesia for a vaso-occlusive crisis of sickle cell disease during pregnancy: a case report.

Authors:  Sören Verstraete; Rik Verstraete
Journal:  J Anesth       Date:  2012-05-10       Impact factor: 2.078

Review 5.  Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy.

Authors:  Babasola O Okusanya; Olufemi T Oladapo
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

6.  Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.

Authors:  Tess E Cooper; Ian R Hambleton; Samir K Ballas; Brydee A Johnston; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2019-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.